FibroBiologics, Inc. Debt Instrument, Fee Amount
FibroBiologics, Inc. (FBLG) had Debt Instrument, Fee Amount of $25.00 million as of 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFeeAmount · last filed 2026-02-24
- 2024-12-31: Debt Instrument, Fee Amount $25.00M; Debt Instrument, Fee Amount as first filed $25.00K.
| Period end | Debt Instrument, Fee Amount | Debt Instrument, Fee Amount as first filed |
|---|---|---|
| 2024-12-31 | $25.00M 10-K · filed 2026-02-24 | $25.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |